Phase 1 Pilot Trial Tests Ustekinumab in Primary Sjögren's Syndrome
A Phase 1 pilot trial explores whether the IL-12/23 blocker ustekinumab is safe and can reduce systemic inflammation in Sjögren's patients.
Summary
Primary Sjögren's Syndrome is a chronic autoimmune disease causing severe dry eyes and mouth, fatigue, and systemic inflammation, with very few approved therapies. This Phase 1 pilot trial, sponsored by the University of Rochester, tested ustekinumab — a biologic drug that blocks the inflammatory cytokines IL-12 and IL-23 — in patients with the condition. The goal was to determine whether the drug is safe in this population and whether it measurably reduces blood-based markers of inflammation. Ustekinumab is already approved for psoriasis and Crohn's disease, where it has shown strong efficacy against similar immune pathways. By repurposing it for Sjögren's, researchers are targeting the Th1 and Th17 immune arms thought to drive glandular and systemic damage. The trial has completed, and its findings could open a new treatment avenue for a disease with significant unmet need.
Detailed Summary
Primary Sjögren's Syndrome (PSS) is a systemic autoimmune disorder that predominantly affects women. It causes progressive destruction of moisture-producing glands, leading to debilitating dryness, fatigue, joint pain, and in serious cases, organ involvement. Disease-modifying therapies remain extremely limited, making new treatment strategies urgently needed.
This Phase 1 pilot trial, sponsored by the University of Rochester, investigated ustekinumab — a monoclonal antibody targeting the p40 subunit shared by interleukin-12 and interleukin-23. These cytokines are central drivers of Th1 and Th17 immune responses, which have been implicated in the pathophysiology of Sjögren's. By blocking these pathways, ustekinumab may dampen aberrant immune activity affecting salivary and lacrimal glands.
The study's stated objectives were to make a preliminary determination of the safety of ustekinumab in PSS patients and to assess the response of systemic measures of inflammation (biomarkers). As a pilot study, it was designed to generate preliminary data rather than confirm efficacy, setting the stage for larger trials if results are promising.
Ustekinumab has an established safety record in other approved indications, and repurposing an already-approved biologic may reduce development risk if this trial demonstrates tolerability and a measurable biomarker response.
The trial is listed as completed on ClinicalTrials.gov, though detailed results are not available from the abstract provided. Any findings would help inform decisions about future Phase 2 efficacy trials in this population.
Key Findings
- Phase 1 pilot trial evaluated ustekinumab in patients with Primary Sjögren's Syndrome.
- Ustekinumab targets the p40 subunit of IL-12 and IL-23, cytokines driving Th1/Th17 pathways implicated in Sjögren's.
- Safety assessment and systemic inflammatory biomarker response were the trial's co-primary aims.
- Repurposing an approved biologic could accelerate treatment availability if pilot data are favorable.
- Trial is listed as completed; published results are not available from the source abstract.
Methodology
This was a Phase 1 pilot trial sponsored by the University of Rochester and listed as completed on ClinicalTrials.gov. It evaluated ustekinumab in patients with Primary Sjögren's Syndrome, with co-primary aims of preliminarily assessing safety and measuring systemic inflammatory biomarker response. Detailed design elements including sample size, dosing regimen, specific biomarker panels, and a published NCT identifier are not available from the source abstract.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full trial data are not publicly available. As a Phase 1 pilot study, it was powered for safety assessment rather than efficacy, meaning no conclusions about clinical benefit can be drawn. Detailed results, including adverse event rates, biomarker outcomes, and patient demographics, remain unpublished from available sources.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.